Loading...
Market
Impact of Imdelltra on Patient Survival Rates by End of 2025
4
Resolution / Starting Odds
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Clinical trial results published in medical journals or major healthcare conferences
Story
Amgen's Imdelltra for Advanced Lung Cancer Wins Accelerated US Approval
May 16, 2024, 07:09 PM
Amgen has received US FDA accelerated approval for its new drug, Imdelltra, designed to treat adult patients with advanced small cell lung cancer. The approval, granted on May 16, 2024, marks a significant step in the fight against this particularly aggressive form of cancer. The drug, also known as tarlatamab, is a targeted immunotherapy aimed at patients whose condition has worsened despite chemotherapy.
View original story
Similar markets
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
No further action • 33%
Additional warnings issued • 33%
Restriction on use broadened • 33%
Adopted in over 20 countries • 25%
Adopted in 10-20 countries • 25%
Adopted in less than 10 countries • 25%
Not adopted as standard treatment • 25%
Stock price increases by over 20% • 33%
Stock price increases by 10-20% • 33%
Stock price increases by less than 10% • 34%
<10% • 25%
10%-25% • 25%
26%-50% • 25%
>50% • 25%
EU only • 25%
UK only • 25%
Japan only • 25%
Multiple regions including EU, UK, and Japan • 25%